Rathi, 200 patient probiotics late treatment RCT: 89% improved recovery [p<0.0001] https://c19p.org/rathi
copied to clipboard
A Randomized Controlled Trial of the Efficacy of Systemic Enzymes and Probiotics in the Resolution of Post-COVID Fatigue
et al., Medicines, doi:10.3390/medicines8090047
RCT 200 long-COVID patients in India, 100 treated with ImmunoSEB and ProbioSEB CSC3, showing improved recovery of post-COVID-19 fatigue with treatment. CTRI/2021/05/033576.The immune effects of probiotics are strain-specific.
|
risk of no recovery, 89.4% lower, RR 0.11, p < 0.001, treatment 9 of 100 (9.0%), control 85 of 100 (85.0%), NNT 1.3, day 14, fatigue.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Rathi et al., 8/30/2021, Double Blind Randomized Controlled Trial, placebo-controlled, India, South Asia, peer-reviewed, 3 authors, trial CTRI/2021/05/033576.
Contact:
akrathi@advancedenzymes.com (corresponding author), swati@advancedenzymes.com, drnehashah772@gmail.com.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.